Details of the Drug

General Information of Drug (ID: DMVTDQ8)

Drug Name
Porfiromycin
Synonyms Porfiromycine; Promycin; ENT-50825; N-methylmitomycin C; U-14743
Indication
Disease Entry ICD 11 Status REF
Head and neck cancer 2D42 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C16H20N4O5
Canonical SMILES
CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4C)N
InChI
InChI=1S/C16H20N4O5/c1-6-10(17)13(22)9-7(5-25-15(18)23)16(24-3)14-8(19(14)2)4-20(16)11(9)12(6)21/h7-8,14H,4-5,17H2,1-3H3,(H2,18,23)/t7-,8+,14+,16-,19?/m1/s1
InChIKey
HRHKSTOGXBBQCB-VFWICMBZSA-N
Cross-matching ID
PubChem CID
13116
CAS Number
801-52-5
UNII
H1WK901OA6
DrugBank ID
DB06478
TTD ID
D0PM9D
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

References

1 ClinicalTrials.gov (NCT02183246) Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients. U.S. National Institutes of Health.